Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans ProgressivaBusiness Wire • 09/25/26
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity PortfolioBusiness Wire • 09/22/26
Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?Zacks Investment Research • 09/22/26
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On StockInvestors Business Daily • 09/11/26
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilGlobeNewsWire • 08/27/26
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/27/26
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo AwarenessBusiness Wire • 08/17/26